| Literature DB >> 34369189 |
Shaofei Ma1, Jing Wang2, Zhanjun Lu3, Chaoying Shi1, Daohua Yang1, Jun Lin1.
Abstract
OBJECTIVE: This article aimed to study the clinicopathological features, immunophenotypes, and differential diagnoses of plexiform fibromyxoma (PF).Entities:
Keywords: Gastrointestinal mesenchymal tumor; clinicopathology; immunohistochemistry; immunophenotype; plexiform angiomyxoid myofibroblastic tumor; plexiform fibromyxoma
Mesh:
Year: 2021 PMID: 34369189 PMCID: PMC8358512 DOI: 10.1177/03000605211027878
Source DB: PubMed Journal: J Int Med Res ISSN: 0300-0605 Impact factor: 1.671
Figure 1.Clinical features of a 67-year-old woman with plexiform fibromyxoma (case 1). (a) Gastroendoscopy revealed a submucosal tumor at the antrum. (b) Gross appearance of the tumor showed a submucosal mass protruding from the mucosal surface. (c) The cut section showing a multinodular, solid glistening translucid tumor.
Figure 2.Pathological findings in a 23-year-old man with plexiform fibromyxoma (case 2). The tumor penetrated the serosa (arrow) and formed extraserosal nodules (star) (HE, ×2)
HE, hematoxylin & eosin.
Figure 3.Histological characteristics of the tumor in case 1. (a) Biopsy sample exhibits a submucosal tumor with ulceration (HE, ×20). (b) The tumor shows a multinodular plexiform growth pattern within the muscularis propria (HE, ×40). (c) The tumor contains spindle-shaped bland tumor cells in the fibromyxoid stroma, which is abundant in small dilated and arborizing vessels with various shapes (HE, ×200). (d) Tumors cells contained round or ovoid nuclei and scanty eosinophilic cytoplasm, and some cells exhibited perinuclear cytoplasmic haloes (HE, ×400).
HE, hematoxylin & eosin.
Figure 4.Histological analysis of case 1. (a) SMA is positive in neoplastic cells (×200). (b) MSA is positive in neoplastic cells (×200). (c) CD117 is negative in neoplastic cells (×200). (d) Ki-67 index is approximately 1% (×200).
SMA, smooth muscle actin; MSA, muscle-specific actin.
Clinicopathologic features of plexiform fibromyxoma.
| Characteristic | Number (%) |
|---|---|
| Age at diagnosis (years), median (range) | 46 (5–81) |
| Sex | |
| Men | 58 (44) |
| Women | 74 (56) |
| Presenting symptom | |
| Abdominal pain or discomfort | 57 (43) |
| Anemia | 20 (15) |
| Melena | 12 (9) |
| Location | |
| Antrum and pylorus | 100 (76) |
| Other | 31 (23) |
| NA | 1 (1) |
| Tumor size (cm), median (range) | 4 (0.8–17) |
| Ulcer | |
| Yes | 53 (40) |
| No | 26 (20) |
| Erosion | 4 (3) |
| NA | 49 (37) |
| Diagnosis | |
| PAMT | 35 (27) |
| PF | 97 (73) |
| Treatment | |
| PG or DG | 79 (60) |
| Other | 27 (20) |
| NA | 26 (20) |
| Follow-up (months), range | 0.7–306 |
PAMT, plexiform angiomyxoid myofibroblastic tumor; PF, plexiform fibromyxoma; PG, partial gastrectomy; DG, Distal gastrectomy; NA, not available.